Abstract
The present invention relates to synthetic and/or recombinant consensus allergens and to their use as allergy vaccines in particular in the treatment of peach-cypress allergy, in the form of an allergy vaccine comprising a consensus allergen and/or a nucleic acid sequence encoding such, wherein the consensus allergen comprises at least (60) amino acids and is derived from a consensus sequence of the amino acid sequences of at least five (5) protein allergens, and wherein said protein allergens share at least 20% amino acid sequence identity.
| Original language | English |
|---|---|
| IPC | C07K 14/ 00 A I |
| Patent number | WO2023242436 |
| Filing date | 05/04/2023 |
| Country/Territory | International Bureau of the World Intellectual Property Organization (WIPO) |
| Priority date | 05/04/2023 |
| Priority number | EP20230166732 |
| Publication status | Published - 21 Dec 2023 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Allergy vaccines based on consensus allergens'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver